CARDAMYST efficacy shown in post-ablation PSVT, but commercial thesis unchanged

What happened

Milestone Pharmaceuticals presented new data at AHA Scientific Sessions 2026 showing CARDAMYST (etripamil) nasal spray converted approximately two-thirds of patients with recurrent PSVT after prior catheter ablation to normal rhythm within 30 minutes. The product's first-and-only approved self-administered indication already gives it a differentiated clinical position, and this analysis extends evidence to a difficult-to-treat subgroup that may struggle with repeat ablation. However, the company's fundamental challenge remains monetization: latest 10-Q showed only $0.6 million in Q2 product revenue despite strong script growth, with heavy gross-to-net deductions and a 7% royalty burden to RTW. The stock trades near $1.27 with a market cap around $158 million, and management has established an ATM facility that could create dilution before commercial traction is proven. While the new data are clinically supportive and may aid physician education or payer discussions, they do not address the core issue of whether CARDAMYST prescriptions will convert into sustainable, clean net sales.

Implication

The AHA data reinforce CARDAMYST’s efficacy in a niche but potentially growing post-ablation population, which could marginally expand the addressable market narrative. However, investors should focus on the next earnings release for net product revenue improvement, prescription depth per prescriber, and any disclosed ATM usage. If the company can show a material step-up in net sales alongside higher coverage, the thesis would strengthen significantly. Conversely, if script growth continues without corresponding revenue and the company taps the ATM, dilution risk escalates and the bear case gains credibility. Until then, the balance of evidence suggests waiting for a better entry point or clearer proof that launch economics are improving.

Thesis delta

The investment thesis remains unchanged: CARDAMYST has real clinical differentiation and early adoption signals, but the stock is a WAIT due to weak revenue conversion and financing overhang. This new efficacy data in post-ablation patients adds to the product’s clinical moat but does not address the economic moat. The catalyst for rerating will be a quarterly filing showing net product revenue above $2 million and no ATM usage, not additional clinical sub-analyses.